MISCAN				SimCRC
Strategy	Discounted costs ($)	Discounted LYG	CER ($)	ICER ($)	Discounted costs ($)	Discounted LYG	CER ($)	ICER ($)
No Screening	2,714,600	0	NA	d	2,295,600	0	NA	d
HII	2,630,600	65.1	CS	---	2,122,000	57.9	CS	d
HS	2,715,300	80.4	10	5,600	2,078,600	76.1	CS	---
IFOBT	2,776,800	79.4	784	d	2,155,700	75.0	CS	d
SIGB	2,823,200	74.3	1,463	d	2,189,100	58.7	CS	d
SIG	2,810,500	76.2	1,258	d	2,176,800	62.4	CS	d
HS (3y) + SIGB	2,798,156	83.1	1,006	d	2,106,646	77.9	CS	d
HS (3y) + SIG	2,857,191	83.7	1,704	d	2,143,225	77.0	CS	d
IFOBT (3y) + SIGB	2,932,676	82.9	2,631	d	2,148,703	77.5	CS	d
IFOBT (3y) + SIG	2,912,349	83.6	2,367	d	2,187,271	76.6	CS	d
HII + SIGB	2,793,800	84.1	941	20,800	2,127,300	79.0	CS	d
HII + SIG	2,840,500	84.6	1,488	d	2,113,600	80.2	CS	8,600
HS + SIGB	2,863,800	87.1	1,714	23,900	2,187,800	84.7	CS	d
HS + SIG	2,909,400	87.1	2,237	d	2,187,000	85.2	CS	14,600
IFOBT + SIGB	3,025,600	87.1	3,569	d	2,282,400	84.6	CS	d
IFOBT + SIG	2,992,800	87.2	3,190	924,800	2,283,000	85.1	CS	d
COL	2,906,100	86.2	2,222	d	2,199,800	85.5	CS	40,200
Stool DNA (3y)*	3,673,500	68.0	14,105	d	3,081,300	64.2	12,233	d
Stool DNA (5y)*	3,383,000	58.8	11,375	d	2,814,300	51.4	10,089	d

LYG = life-years gained vs. no screening; ICER = incremental cost-effectiveness ratio; CER = cost-effectiveness ratio compared with no screening; HII = annual Hemoccult II, HS = annual Hemoccult SENSA; IFOBT = annual immunochemical fecal occult blood test; SIG = 5-yearly sigmoidoscopy without biopsy; SIGB = 5-yearly sigmoidoscopy with biopsy; HS (3y) = 3-yearly Hemoccult SENSA; iFOBT (3y) = 3-yearly immunochemical fecal occult blood test; COL = 10-yearly colonoscopy; d = dominated; --- indicates default strategy (i.e., the least costly and least effective non-dominated strategy); NA = not applicable

^*The two stool DNA strategies are not competing options. They are shown here together for comparison purposes only. The ICERs are assessed separately using each stool DNA strategy in turn.